Niraparib
- Generic Name
- Niraparib
- Brand Names
- Zejula
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O
- CAS Number
- 1038915-60-4
- Unique Ingredient Identifier
- HMC2H89N35
- Background
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
- Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
- Associated Therapies
- Maintenance therapy
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03955471
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 58
- Registration Number
- NCT03945084
- Locations
- 🇮🇹
Azienda Sanitaria Locale CN2 - Alba e Bra, Alba, Italy
🇮🇹Azienda USL Toscana Sud Est, Ospedale San Donato, Arezzo, Italy
🇮🇹Istituto Tumori Giovanni Paolo II - IRCCS, Bari, Italy
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03945721
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2021-10-22
- Target Recruit Count
- 41
- Registration Number
- NCT03925350
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT03895788
- Locations
- 🇨🇳
Jing Wang, Changsha, Hunan, China
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03891615
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer)
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 83
- Registration Number
- NCT03891576
- Locations
- 🇩🇪
University Hospital Dresden, Dresde, Germany
🇮🇹ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹ASST di Lecco, Lecco, Italy
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 645
- Registration Number
- NCT03869190
- Locations
- 🇪🇸
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Taiwan University Hospital, Yun-Lin Branch, Huwei Township, Taiwan
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Shadia Jalal, MD
- Target Recruit Count
- 14
- Registration Number
- NCT03840967
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT03830918
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.